Leukemia Research
Volume 24, Issue 4 , Pages 349-352 , April 2000

Poor clinical significance of p53 gene polymorphism in acute myeloid leukemia

  • Yasuyuki Nakano

      Affiliations

    • Department of Infectious Diseases, Nagoya University School of Medicine, Nagoya, 466-8560 Japan
    • ,
  • Tomoki Naoe

      Affiliations

    • Department of Infectious Diseases, Nagoya University School of Medicine, Nagoya, 466-8560 Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81-53-744-2955; fax: +81-52-744-2801
    • ,
  • Hitoshi Kiyoi

      Affiliations

    • Department of Infectious Diseases, Nagoya University School of Medicine, Nagoya, 466-8560 Japan
    • ,
  • Shinji Kunishima

      Affiliations

    • Department of Medicine, Japanese Red Cross Aichi Blood Centre, Seto, Japan
    • ,
  • Saburo Minami

      Affiliations

    • Department of Medicine, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan
    • ,
  • Shuichi Miyawaki

      Affiliations

    • Department of Medicine, Saiseikai Maebashi Hospital, Maebashi, Japan
    • ,
  • Norio Asou

      Affiliations

    • Second Department of Internal Medicine, Kumamoto University School of Medicine, Kumamoto, Japan
    • ,
  • Kazutaka Kuriyama

      Affiliations

    • Department of Hematology, Atomic Disease Institute Nagasaki University School of Medicine, Nagasaki, Japan
    • ,
  • Hidehiko Saito

      Affiliations

    • First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan
    • ,
  • Ryuzo Ohno

      Affiliations

    • Department of Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan

Received 28 August 1999 ,Accepted 18 October 1999.

References 

  1. Frebourg T, Friend SH. Cancer risks from germline p53 mutations. J. Clin. Invest. 1992;90:1637
  2. Moreau F, Matlashewski G. Molecular analysis of different allelic variants of wild-type human p53. Biochem. Cell. Biol. 1992;70:1014
  3. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol. Cell. Biol. 1987;7:961
  4. Olschwang S, Laurent-Puig P, Vassal A, Salmon RJ, Thomas G. Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population. Hum. Genet. 1991;86:369
  5. Zhang W, Hu G, Deisseroth A. Polymorphism at codon 72 of the p53 gene in human acute myelogenous leukemia. Gene. 1992;117:271
  6. Kawajiri K, Eguchi H, Nakachi K, Sekiya T, Yamamoto M. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res. 1996;56:72
  7. Murata M, Tagawa M, Kimura M, Kimura H, Watanabe S, Saisho H. Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis. 1996;17:261
  8. Storey A, Thomas M, Kalita A, et al.  Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998;393:229
  9. Helland A, Langerod A, Johnsen H, Olsen AO, Skovlund E, Borresen-Dale AL. p53 polymorphism and risk of cervical cancer. Nature. 1998;396:530
  10. Josefsson AM, Magnusson PK, Ylitalo N, et al.  p53 polymorphism and risk of cervical cancer. Nature. 1998;396:531
  11. Hildesheim A, Schiffman M, Brinton LA, et al.  p53 polymorphism and risk of cervical cancer. Nature. 1998;396:531
  12. Sonoda Y, Saigo PE, Boyd J. p53 and genetic susceptibility to cervical cancer. J. Natl. Cancer. Inst. 1999;91:557
  13. Kiyoi H, Naoe T, Nakano Y, et al.  Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93:3074
  14. Dastugue N, Payen C, Lafage-Pochitaloff M, et al.  Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. Leukemia. 1995;9:1491
  15. Nakano Y, Kiyoi H, Miyawaki S, Asou N, Ohno R, Saito H, et al. Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene. Br. J. Haematol. 1999;104:659
  16. Prives C. Signaling to p53: breaking the MDM2-p53 circuit. Cell. 1998;95:5
  17. Preudhomme C, Fenaux P. The clinical significance of mutations of the P53 tumour suppressor gene in haematological malignancies. Br. J. Haematol. 1997;98:502
  18. Szekely L, Selivanova G, Magnusson KP, Klein G, Wiman KG. EBNA-5, an Epstein–Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc. Natl. Acad. Sci. USA. 1993;90:5455

PII: S0145-2126(99)00187-3

Leukemia Research
Volume 24, Issue 4 , Pages 349-352 , April 2000

Article Tools

* Image Usage & Resolution